Best Practices in Chronic Myeloid Leukemia Monitoring and Management

about

Assessment of the Number and Phenotype of Macrophages in the Human BMB Samples of CML.Effects of nilotinib on leukaemia cells using vibrational microspectroscopy and cell cloning.Rapid Screening for Deleted Form of β-thalassemia by Real-Time Quantitative PCR.

P2860

Q37483248-23A0A7C5-3036-4230-A9F4-C96B2E27551A Q39109560-DCD50BA2-6746-462C-8B26-137CAA090E52 Q47861448-72FB1B12-D911-45E2-961A-9046BFB3FE33

P2860

Best Practices in Chronic Myeloid Leukemia Monitoring and Management

Item

http://www.wikidata.org/entity/Q36884361

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Best Practices in Chronic Myeloid Leukemia Monitoring and Management

@en

type

Item

label

Best Practices in Chronic Myeloid Leukemia Monitoring and Management

@en

prefLabel

Best Practices in Chronic Myeloid Leukemia Monitoring and Management

@en

P1476

Best Practices in Chronic Myeloid Leukemia Monitoring and Management

@en

P2093

Caterina De Benedittis

http://www.w3.org/2001/XMLSchema#string

Manuela Mancini

http://www.w3.org/2001/XMLSchema#string

P2860

AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance

Structural mechanism of the Pan-BCR-ABL inhibitor ponatinib (AP24534): lessons for overcoming kinase inhibitor resistance

Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining

Detection of BCR-ABL transcripts in chronic myeloid leukemia (CML) using an in situ RT-PCR assay.

Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using 'real-time' quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) - a Europe against cancer program.

Sequential homoharringtonine and interferon-alpha in the treatment of early chronic phase chronic myelogenous leukemia.

Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation.

Phase 2 study of subcutaneous omacetaxine mepesuccinate for chronic-phase chronic myeloid leukemia patients resistant to or intolerant of tyrosine kinase inhibitors.

P304

626-633

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1634/THEONCOLOGIST.2015-0337

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Simona Soverini

Giovanni Martinelli

P577

2016-03-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27032870

http://www.w3.org/2001/XMLSchema#string

P921

chronic myeloid leukemia

best practice

P932

4861357

http://www.w3.org/2001/XMLSchema#string

Best Practices in Chronic Myeloid Leukemia Monitoring and Management

about

P2860

P2860

Best Practices in Chronic Myeloid Leukemia Monitoring and Management

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921

P932